Market LIVE
Published markets; coverage varies by country
Product profile · United States

ELIQUIS

 ·  Patent Litigation & Settlement History ↓

IngredientAPIXABAN
Application typeNDA
Application202155
Product002
Dosage formTABLET
RouteORAL
Strength5MG
Approval date2012-12-28
Marketing statusPrescription
Status event—
ApplicantBRISTOL MYERS SQUIBB
Product source

Current GenericRadar decision

Year2019
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2019-12-23
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2019-12-23
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
69672082026-11-21DS/DP/U U-1301———
———
69672082026-11-21DS/DP/U U-4178———
———
69672082026-11-21DS/DP/U U-1323———
———
69672082026-11-21DS/DP/U U-1302———
———
69672082026-11-21DS/DP/U U-1200———
———
69672082027-05-21— ————
—2027-05-21—
93269452031-02-24DP ————
———
93269452031-08-24— ————
—2031-08-24—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NPP—2028-04-17————Source
PED—2028-10-17————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
209944 / 002APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED——SUNSHINE LAKENEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210053 / 002APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED——SIGMAPHARM LABS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210133 / 002APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED——PRINSTON PHARMA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210171 / 002APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED——SUN PHARM INDUSTRIESNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210013 / 002FINAL_APPROVAL · FINAL_APPROVED2019-12-23—MICRO LABS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210128 / 002FINAL_APPROVAL · FINAL_APPROVED2019-12-23—MYLAN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210152 / 002FINAL_APPROVAL · FINAL_APPROVED2020-04-08—BIONPHARMA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210180 / 002FINAL_APPROVAL · FINAL_APPROVED2020-07-28—ACCORD HEALTHCARE INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209898 / 002FINAL_APPROVAL · FINAL_APPROVED2020-09-11—REGCON HOLDINGS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209845 / 002FINAL_APPROVAL · FINAL_APPROVED2021-07-26—BRECKENRIDGE PHARMACEUTICAL INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210185 / 002FINAL_APPROVAL · FINAL_APPROVED2023-02-27—ZYDUS PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210026 / 002FINAL_APPROVAL · FINAL_APPROVED2023-05-26—AUROBINDO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210066 / 002FINAL_APPROVAL · FINAL_APPROVED2023-11-21—HETERO LABS LTD UNIT VNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210091 / 002FINAL_APPROVAL · FINAL_APPROVED2024-02-16—APOTEX INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210156 / 002FINAL_APPROVAL · FINAL_APPROVED2024-12-17—TORRENT PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209810 / 002FINAL_APPROVAL · FINAL_APPROVED2025-02-14—IMPAX LABORATORIES LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210067 / 002FINAL_APPROVAL · FINAL_APPROVED2025-02-27—MACLEODS PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 13 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
210013 / 002MICRO LABS LTDFINAL_APPROVAL · FINAL_APPROVED2019-12-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210128 / 002MYLAN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2019-12-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210152 / 002BIONPHARMA INCFINAL_APPROVAL · FINAL_APPROVED2020-04-08 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210180 / 002ACCORD HEALTHCARE INCFINAL_APPROVAL · FINAL_APPROVED2020-07-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209898 / 002REGCON HOLDINGS LLCFINAL_APPROVAL · FINAL_APPROVED2020-09-11 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209845 / 002BRECKENRIDGE PHARMACEUTICAL INCFINAL_APPROVAL · FINAL_APPROVED2021-07-26 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210185 / 002ZYDUS PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2023-02-27 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210026 / 002AUROBINDO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2023-05-26 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210066 / 002HETERO LABS LTD UNIT VFINAL_APPROVAL · FINAL_APPROVED2023-11-21 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210091 / 002APOTEX INCFINAL_APPROVAL · FINAL_APPROVED2024-02-16 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210156 / 002TORRENT PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2024-12-17 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209810 / 002IMPAX LABORATORIES LLCFINAL_APPROVAL · FINAL_APPROVED2025-02-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210067 / 002MACLEODS PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2025-02-27 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2019-12-23TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

Event datePartyEvent Licensed entryEvidenceSource
Not disclosed Multiple generic applicants SETTLEMENT
Brand-level record; strength scope not established
2028-04-01 REVIEW —
Earlier entry contingent on patent outcomes